Abstract 868P
Background
Many patients with oral (OSCC) and oropharyngeal squamous cell carcinoma (OPSCC) experience disease recurrence after surgery with curative intent despite R0 resection and adjuvant treatment. Several methods, including frozen section analysis, are available to evaluate surgical margins. However, precancerous epigenetic disturbances may predate morphological changes. This study aimed to address the unmet need for intraoperative recurrence prediction based on molecular features in clear resection margins.
Methods
Infinium EPIC BeadChip 850k methylation analysis of 71 OPSCC primary tumors (TU), 16 contralateral healthy mucosa (HM), and 70 resection margins (RM: OPSCC & OSCC) was conducted. Oncogenic features were selected based on TU vs. HM differential methylation analysis (Kruskal Wallis Tests: η2 > 0.14 and FDR < 0.05). Baseline classifiers were trained, and the best-performing classifier was optimized by hyperparameter tuning and feature selection, allowing the integration of 46 TCGA R0 margin (normal adjacent tissue) data. Features selected were checked for common single nucleotide polymorphisms (SNP), and correlation analysis between loci methylation and gene expression (RNAseq) was conducted. Four margin samples analyzed with Epic BeadChip were also sequenced with Oxford Nanopore Technology (ONT) Mk1C.
Results
Forty-nine thousand features were selected to train six baseline classifiers, and XGBoost was chosen. XGBoost training with 10-fold cross-validation, hyperparameter tuning, and seven features (hypomethylated in TU compared to HM) selection led to the construction of a classifier model that predicts recurrence with a mean area under the ROC curve (AUC) of 0.80 (95% CI = 0.73 - 0.87). None of the seven loci used in constructing the model harbored a common SNP (MAF < 0.01). A significant correlation between the methylation level of five of the CpG loci and RNA expression was discovered (p < 0.05). ONT methylation output exhibited a strong positive correlation with Epic BeadChip for all the intersected loci (r = 0.83, p < 0.001), but most importantly, the seven selected features (r = 0.90, p < 0.001).
Conclusions
Disease recurrence can be predicted from morphologically clear surgical margins using a methylation classifier.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Research Training Group GRK-2254 (HEIST, 288342734) funded by Deutsche Forschungsgemeinschaft (DFG).
Disclosure
S. Laban: Other, Institutional, Advisory Board: Merck Sharp & Dohme, Bristol Myers Squibb, Sanofi Genzyme; Financial Interests, Institutional, Advisory Board, Travel reimbursement: AstraZeneca ; Financial Interests, Institutional, Other, Travel reimbursement: Merck Serono. All other authors have declared no conflicts of interest.
Resources from the same session
880P - ctHPV16-DNA in Liquid Biopsy: A promising biomarker to monitor disease status in patients with HPV-positive oropharyngeal squamous cell carcinoma
Presenter: Nora Würdemann
Session: Poster session 12
881P - SOTO study: Prospective study to correlate the treatment sensitivity of patient-derived organoids (PDOs) with treatment outcomes in head and neck cancer patients
Presenter: Ifigenia Vasiliadou
Session: Poster session 12
882P - Claudin-1 (CLDN1) expression in head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Stefano Cavalieri
Session: Poster session 12
884P - Prognostic value and immune characteristics of LGALS1 in head and neck squamous cell carcinoma
Presenter: Yanfei Min
Session: Poster session 12
885P - Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in nasopharyngeal carcinoma
Presenter: Dingyi Wang
Session: Poster session 12
887P - Antitumor activity of the radioenhancer NBTXR3 on injected lesions to estimate overall survival: Exploratory analyses from a phase I in cisplatin-ineligible locally advanced HNSCC patients
Presenter: Christophe Le Tourneau
Session: Poster session 12
888P - Phase I study of olaparib combined with loco-regional radiotherapy in patients with head and neck squamous cell carcinoma
Presenter: Marcel Verheij
Session: Poster session 12
889P - CT-based radiomics models to predict progression in locally advanced head and neck cancer treated with definitive chemoradiation
Presenter: Gema Bruixola
Session: Poster session 12